关联交易决策制度

Search documents
海尔智家: 海尔智家股份有限公司关联(连)交易公允决策制度(2025年修订)
Zheng Quan Zhi Xing· 2025-05-28 12:26
General Principles - The company establishes a fair decision-making system for related transactions to ensure compliance with laws and regulations, protecting the interests of the company and all shareholders [1][2][3] - Related transactions are defined as transactions between the company, its subsidiaries, and related parties, adhering to the definitions set by relevant stock exchange rules [2][3] Basic Principles of Related Transactions - Related transactions must follow principles of equality, voluntariness, equivalence, and fairness, ensuring they align with the overall interests of the company and shareholders [2][4] - Shareholders and directors with a related interest must abstain from voting on related transaction matters [2][4] Scope of Related Parties and Transactions - Related parties include individuals and entities defined by stock exchange rules, such as major shareholders and directors [3][5] - The company must disclose related transactions that meet specific thresholds, including asset purchases and financial assistance [6][7] Management of Related Transactions - Departments must report details of proposed related transactions to the securities department for preliminary review [11][12] - The company must comply with stock exchange rules regarding the approval process for related transactions, including necessary disclosures [14][15] Decision-Making Procedures - Related transactions exceeding certain financial thresholds require approval from the board of directors or shareholders [16][17] - Independent directors must provide opinions on the fairness and reasonableness of related transactions [19][20] Information Disclosure - The company must disclose related transactions promptly after board or shareholder approval, adhering to stock exchange requirements [24][25] - Continuous related transactions must be disclosed in annual and semi-annual reports, including their execution status [18][19] Exemptions and Special Cases - Certain transactions may be exempt from disclosure and approval requirements if they meet specific criteria, such as low financial thresholds or being part of regular business operations [28][29] - The company must ensure that any financial services agreements with related parties are disclosed, including terms and conditions [22][23]
乐心医疗: 关联交易决策制度(2025年05月)
Zheng Quan Zhi Xing· 2025-05-23 10:54
关联交易决策制度 广东乐心医疗电子股份有限公司 关联交易决策制度 第一章 总 则 第一条 为了更好地规范广东乐心医疗电子股份有限公司(以下简称"公司")关联交易决 策,保护全体股东的合法权益,根据《中华人民共和国公司法》(以下简称"《公司法》") 《中华人民共和国证券法》《深圳证券交易所创业板股票上市规则》等法律、法规、规范性文件 及《广东乐心医疗电子股份有限公司章程》(以下简称"《公司章程》")的有关规定,制定 广东乐心医疗电子股份有限公司关联交易决策制度(以下简称"本制度")。 第二条 公司关联交易是指公司或者其控股子公司与公司关联人之间发生的转移资源或者义 务的事项,包括以下交易: 关联交易决策制度 第三条 公司在确认关联关系和处理关联交易时,应遵循并贯彻以下原则: (一)尽量避免或减少与关联人之间的关联交易; (二)确定关联交易价格时,应遵循"公平、公正、公开、等价有偿"原则,原则上不偏离 市场独立第三方的标准,对于难以比较市场价格或订价受到限制的关联交易,应以成本加合理利 润的标准确定关联交易价格; 第二章 关联人范围的界定 第四条 公司关联人包括关联法人和关联自然人。 第五条 具有下列情形之一的法 ...
上海凤凰: 上海凤凰关联交易决策制度
Zheng Quan Zhi Xing· 2025-05-22 14:35
上海凤凰企业(集团)股份有限公司 关联交易决策制度 第二章 关联人及关联交易认定 第六条 公司的关联人包括关联法人(或者其他组织)和关联自然人。 具有以下情形之一的法人(或者其他组织),为公司的关联法人(或者其他 组织): (一)直接或者间接控制公司的法人(或者其他组织); 第一章 总 则 第一条 为规范上海凤凰企业(集团)股份有限公司(以下简称公司)及控 股子公司的关联交易行为,提高公司规范运作水平,保护公司和全体股东的合法 权益,根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交 易所股票上市规则》(以下简称《股票上市规则》)、《上海证券交易所上市公 司自律监管指引第 5 号—交易与关联交易》等法律、行政法规、规范性文件和公 司章程等有关规定,制定本制度。 第二条 公司应建立健全交易与关联交易的内部控制制度,明确交易与关联 交易的决策权限和审议程序,并在关联交易审议过程中严格实施关联董事和关联 股东回避表决制度。 公司交易与关联交易行为应当定价公允、审议程序合规、信息披露规范。 第三条 公司交易与关联交易行为应当合法合规,不得隐瞒关联关系,不得 通过将关联交易非关联化规避相关审议程序和信息披 ...
仁智股份: 关联交易决策制度(2025年5月)
Zheng Quan Zhi Xing· 2025-05-19 09:38
浙江仁智股份有限公司 关联交易决策制度 二○二五年五月 第一章 总 则 第1条 为保证浙江仁智股份有限公司(以下简称"公司")与关联人之间订立的关 联交易符合公平、公正、公开的原则,确保公司的关联交易行为不损害公 司和全体股东的利益,根据《中华人民共和国公司法》《中华人民共和国 证券法》 《深圳证券交易所股票上市规则》 (以下简称"《上市规则》")、 第二章 关联人和关联关系 公司应当及时更新关联人名单并将上述关联人情况及时向深圳证券交易 所备案。 第9条 公司的关联交易,是指公司或其控股子公司与公司关联人之间发生的转 移资源或义务的事项,包括: -2- 第10条 公司在确认和处理有关关联人之间关联关系与关联交易时,须遵循并贯 彻以下原则: 以比较市场价格或定价受到限制的关联交易,应通过合同明确有关成 本和利润的标准。 第四章 关联交易的决策程序 第11条 公司董事会审议关联交易事项时,关联董事应当回避表决,也不得代理其 -3- 他董事行使表决权,其表决权不计入表决权总数。该董事会会议由过半数 的非关联董事出席即可举行,董事会会议所做决议须经非关联董事过半 数通过。出席董事会的非关联董事人数不足三人的,公司应 ...
沃尔核材: 关联交易公允决策制度(2025年5月)
Zheng Quan Zhi Xing· 2025-05-12 13:40
关 联 交 易 公 允 决 策 制 度 二○二五年五月 关联交易公允决策制度 目 录 关联交易公允决策制度 第一章 总则 第一条 为保证深圳市沃尔核材股份有限公司(以下简称"公司"或"本公 司")与关联方之间订立的关联交易符合公平、公正、公开的原则以及监管部门 的规范要求,本公司根据《中华人民共和国公司法》《中华人民共和国证券法》 《深圳证券交易所股票上市规则》(以下简称"《深交所上市规则》")、《深 圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》等有关法 律、法规、规范性文件和《深圳市沃尔核材股份有限公司章程》(以下简称"《公 司章程》")的有关规定,制定本制度。 (四)与关联方有任何利害关系的董事、股东及当事人就该事项进行表决时, 应采取回避原则; (五)必要性原则。公司董事会应当根据客观标准判断关联交易是否必要, 是否会损害公司利益,必要时应当聘请专业评估师或独立财务顾问发表意见。 第三条 本公司及本公司全资、控股子公司涉及关联交易的决策管理和信息 披露等事项均应当遵守本制度的相关规定。 第二章 关联人和关联关系 第四条 本公司关联人包括关联法人(或其他组织)和关联自然人。 具有以下 ...
方直科技: 关联交易决策制度(2025年5月修订)
Zheng Quan Zhi Xing· 2025-05-12 12:05
General Principles - The company establishes a system for managing related party transactions to protect the legal interests of shareholders and creditors, especially minority investors [2] - Related party transactions include resource or obligation transfers between the company or its subsidiaries and related parties, such as investments and financial management [2][3] Related Parties Definition - Related parties include both legal entities and natural persons that may influence the company's interests, such as major shareholders and their family members [3][4] Approval and Disclosure Procedures - Transactions exceeding 300,000 yuan with related natural persons or 3 million yuan with related legal entities must be approved by independent directors and disclosed [5][6] - Daily related party transactions can be estimated annually, and any excess must undergo re-approval and disclosure [5][8] Pricing Principles - Pricing for related party transactions should follow principles such as state pricing, market pricing, or mutually agreed pricing [4][5] Board and Shareholder Meeting Protocols - Related directors and shareholders must abstain from voting on related party transactions to ensure impartiality [6][7] - The board meeting can proceed with a majority of non-related directors, and if fewer than three non-related directors are present, the transaction must be submitted to the shareholders' meeting [6][7] Information Disclosure - The company must disclose details of related party transactions, including agreements and pricing basis, in accordance with regulatory requirements [8][9] - Certain transactions, such as public tenders or cash donations, may be exempt from shareholder meeting approvals [9]
康缘药业: 江苏康缘药业股份有限公司关联交易决策制度(草案)
Zheng Quan Zhi Xing· 2025-04-02 13:20
Core Viewpoint - The document outlines the regulations and procedures for related party transactions of Jiangsu Kangyuan Pharmaceutical Co., Ltd, emphasizing fairness, legality, and the protection of shareholders' interests, particularly those of minority shareholders [1][2][3]. Group 1: General Principles - The company must ensure that related party transactions are fair, transparent, and do not harm the interests of the company or its shareholders, especially minority shareholders [1]. - Related party transactions should maintain the company's independence and must not be used to manipulate financial indicators [1][2]. - The regulations are binding on shareholders, directors, and management, who must comply with these rules [1]. Group 2: Identification of Related Parties - Related parties include both legal entities and natural persons that have significant control or ownership over the company [2][3]. - Legal entities that control the company or are controlled by significant shareholders (holding over 5% of shares) are considered related parties [2]. - Natural persons who hold over 5% of shares or are directors, supervisors, or senior management of the company are also classified as related parties [2][3]. Group 3: Recognition of Related Transactions - Related transactions include resource transfers or obligations between the company and its related parties, such as asset purchases, investments, and financial assistance [5]. - Transactions with amounts exceeding 300,000 yuan for natural persons or 3 million yuan for legal entities require board approval and disclosure [5][6]. - Independent directors must review and approve significant related transactions before they are submitted to the board for approval [6][7]. Group 4: Decision-Making Procedures - Related transactions must be reviewed by non-related directors, and related directors must abstain from voting [23][25]. - The company must disclose details of related transactions, including the nature of the relationship and transaction terms [27][28]. - Certain transactions may be exempt from the usual review and disclosure requirements if they do not involve payment or obligations [29][30]. Group 5: Amendments and Effectiveness - The regulations are subject to revision by the company's board and will take effect upon approval by the shareholders' meeting [33][34]. - The previous related transaction decision-making system established in July 2007 is hereby abolished [34].